We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now?
Read MoreHide Full Article
Key Takeaways
Liquidia's Yutrepia is gaining market share, with more than 5,000 patients started on therapy as of July 2026.
Yutrepia's expansion plans include SSc-RP, COPD-associated PH, IPF and progressive pulmonary fibrosis.
LQDA faces patent litigation, competitive pressure, rising R&D costs and heavy reliance on Yutrepia.
Shares of Liquidia Corporation (LQDA - Free Report) have lost 13.9% in a month against the industry’s growth of 1.5%. The stock has lagged the broader sector and the S&P 500 Index.
The selloff accelerated after Liquidia reported second-quarter results on Aug. 12. Although earnings and revenues exceeded consensus estimates, the upside was relatively modest, leaving investors unimpressed and weighing on the stock.
The recent pullback has also erased part of the strong gains LQDA delivered earlier in 2026. Against this backdrop, investors may want to weigh Liquidia’s key growth drivers against the risks and challenges facing the company to determine whether the stock’s long-term opportunity remains compelling.
LQDA Underperforms Industry, Sector and S&P 500 Index
Image Source: Zacks Investment Research
LQDA’s Yutrepia Gains Traction
Lead drug Yutrepia is an inhaled dry-powder formulation of treprostinil developed using Liquidia’s proprietary PRINT technology. The technology delivers the drug deeper into the lungs through an easy-to-use inhaler while enabling higher doses than other inhaled treprostinil therapies.
Launched in June 2025, Yutrepia was approved by the FDA in May 2025 for the treatment of both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
As of July 31, 2026, Liquidia had received approximately 5,900 unique prescriptions since launch and started more than 5,000 patients on therapy.
More than 1,100 physicians had prescribed Yutrepia since its launch as of July 31, with more than 30% having written prescriptions for at least five patients. The prescription-to-start conversion rate remained above 85%.
Yutrepia appears to be gaining market share while expanding the inhaled prostacyclin market.
Liquidia currently generates revenues from sales of Yutrepia inhalation powder, and through a profit-sharing arrangement with Sandoz under a promotion agreement originally signed in August 2018 and subsequently amended. The agreement allows Liquidia to share in the profits generated from sales of Sandoz's generic Treprostinil Injection in the United States.
Treprostinil Injection is a fully substitutable generic formulation of treprostinil for parenteral administration in the United States. Liquidia holds exclusive rights to commercialize the product and collaborates with Sandoz on its commercial strategy.
However, Sandoz retains ownership of Treprostinil Injection and holds the associated abbreviated new drug application.
LQDA Works to Expand Yutrepia’s Label
LQDA plans to explore Yutrepia in additional indications, including pulmonary hypertension associated with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF) and Raynaud’s phenomenon associated with systemic sclerosis (SSc-RP).
The FDA recently granted Fast Track designation to Yutrepia inhalation powder for the treatment of SSc-RP.
For Liquidia, the designation enables more frequent interactions with the FDA during development, allows for the potential rolling review of a new drug application, and, if applicable criteria are met, may support eligibility for priority review and/or accelerated approval.
Liquidia plans to initiate RE-WARM, a phase IIa, randomized, open-label, dose-finding study of Yutrepia in approximately 75 adults with SSc experiencing symptomatic Raynaud's phenomenon attacks. RE-WARM is expected to begin in October 2026, with primary completion targeted for February 2027.
Liquidia is also developing L606, an investigational liposomal formulation of treprostinil licensed from Pharmosa Biopharm, designed for twice-daily administration using a short-duration, next-generation nebulizer. It is also being evaluated in PAH and PH-ILD. The phase III Re-Spire study on L606 is currently enrolling.
LQDA’s Overdependence on Yutrepia
While Yutrepia remains the key driver of LQDA’s top-line growth, the company continues to rely heavily on the drug as its primary source of revenue expansion. This dependence creates concentration risk, particularly given Liquidia’s relatively lean pipeline and limited number of near-term growth opportunities beyond Yutrepia.
Adding to the risk profile is Liquidia’s ongoing patent dispute with United Therapeutics (UTHR - Free Report) concerning Yutrepia’s use in PH-ILD. Management has stated that an adverse ruling could result in royalty obligations or other injunctive or adjunctive relief. With a decision potentially coming at any time, the litigation represents a headwind that could adversely impact Yutrepia’s economics, market opportunity or commercialization prospects.
LQDA’s Valuation and Estimate Movement
Going by the price/sales ratio, LQDA shares currently trade at 6.10X forward sales, higher than the industry’s average of 1.89X but lower than its mean of 14.67X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 earnings per share (EPS) has moved south to $2.57 from $3.02, and that for 2027 EPS has declined to $4.38 from $4.92 in the past 60 days.
Image Source: Zacks Investment Research
Avoid LQDA for Now
Liquidia's products and pipeline candidates for PAH compete across several established and clinically validated treatment pathways. UTHR markets four medicines in the United States to treat PAH, namely Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; under an in-license from Eli Lilly and Company) tablets. Remodulin is approved for both subcutaneous and intravenous use.
Insmed (INSM - Free Report) is also advancing several clinical-stage programs in respiratory diseases, including TPIP and INS1148. TPIP is an inhaled dry powder formulation of the treprostinil prodrug treprostinil palmitil, which may offer a differentiated product profile for PH-ILD, PAH, PPF and IPF.
Despite Yutrepia’s strong launch and encouraging commercial traction, Liquidia’s investment case remains exposed to several meaningful risks. The company continues to be heavily dependent on Yutrepia for growth, while its relatively lean pipeline provides limited diversification.
Any slowdown in prescription growth, reimbursement challenges or increasing competitive pressure could therefore have a material impact on Liquidia’s revenue trajectory and overall growth prospects.
The ongoing patent litigation with UTHR over Yutrepia’s use in PH-ILD represents another significant overhang. An adverse ruling could restrict commercialization, remove the PH-ILD indication or result in monetary damages, creating substantial uncertainty around Yutrepia’s long-term commercial opportunity.
Meanwhile, competition from established PAH therapies could make it increasingly difficult for Yutrepia to sustain its momentum and capture meaningful market share.
While 2026 and 2027 EPS estimates have declined, rising R&D expenses could further weigh on profitability and limit the potential for meaningful earnings leverage in the near term.
Overall, LQDA’s heavy reliance on Yutrepia, ongoing litigation risk, competitive pressures, elevated valuation and rising costs create an unfavorable risk-reward profile.
Hence, we recommend that both current and prospective investors avoid the stock for now.
View the Zacks #1 Rank List
Image: Bigstock
LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now?
Key Takeaways
Shares of Liquidia Corporation (LQDA - Free Report) have lost 13.9% in a month against the industry’s growth of 1.5%. The stock has lagged the broader sector and the S&P 500 Index.
The selloff accelerated after Liquidia reported second-quarter results on Aug. 12. Although earnings and revenues exceeded consensus estimates, the upside was relatively modest, leaving investors unimpressed and weighing on the stock.
The recent pullback has also erased part of the strong gains LQDA delivered earlier in 2026. Against this backdrop, investors may want to weigh Liquidia’s key growth drivers against the risks and challenges facing the company to determine whether the stock’s long-term opportunity remains compelling.
LQDA Underperforms Industry, Sector and S&P 500 Index
Image Source: Zacks Investment Research
LQDA’s Yutrepia Gains Traction
Lead drug Yutrepia is an inhaled dry-powder formulation of treprostinil developed using Liquidia’s proprietary PRINT technology. The technology delivers the drug deeper into the lungs through an easy-to-use inhaler while enabling higher doses than other inhaled treprostinil therapies.
Launched in June 2025, Yutrepia was approved by the FDA in May 2025 for the treatment of both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
As of July 31, 2026, Liquidia had received approximately 5,900 unique prescriptions since launch and started more than 5,000 patients on therapy.
More than 1,100 physicians had prescribed Yutrepia since its launch as of July 31, with more than 30% having written prescriptions for at least five patients. The prescription-to-start conversion rate remained above 85%.
Strong Yutrepia sales helped drive the company's fourth consecutive profitable quarter.
Yutrepia appears to be gaining market share while expanding the inhaled prostacyclin market.
Liquidia currently generates revenues from sales of Yutrepia inhalation powder, and through a profit-sharing arrangement with Sandoz under a promotion agreement originally signed in August 2018 and subsequently amended. The agreement allows Liquidia to share in the profits generated from sales of Sandoz's generic Treprostinil Injection in the United States.
Treprostinil Injection is a fully substitutable generic formulation of treprostinil for parenteral administration in the United States. Liquidia holds exclusive rights to commercialize the product and collaborates with Sandoz on its commercial strategy.
However, Sandoz retains ownership of Treprostinil Injection and holds the associated abbreviated new drug application.
LQDA Works to Expand Yutrepia’s Label
LQDA plans to explore Yutrepia in additional indications, including pulmonary hypertension associated with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF) and Raynaud’s phenomenon associated with systemic sclerosis (SSc-RP).
The FDA recently granted Fast Track designation to Yutrepia inhalation powder for the treatment of SSc-RP.
For Liquidia, the designation enables more frequent interactions with the FDA during development, allows for the potential rolling review of a new drug application, and, if applicable criteria are met, may support eligibility for priority review and/or accelerated approval.
Liquidia plans to initiate RE-WARM, a phase IIa, randomized, open-label, dose-finding study of Yutrepia in approximately 75 adults with SSc experiencing symptomatic Raynaud's phenomenon attacks. RE-WARM is expected to begin in October 2026, with primary completion targeted for February 2027.
Liquidia is also developing L606, an investigational liposomal formulation of treprostinil licensed from Pharmosa Biopharm, designed for twice-daily administration using a short-duration, next-generation nebulizer. It is also being evaluated in PAH and PH-ILD. The phase III Re-Spire study on L606 is currently enrolling.
LQDA’s Overdependence on Yutrepia
While Yutrepia remains the key driver of LQDA’s top-line growth, the company continues to rely heavily on the drug as its primary source of revenue expansion. This dependence creates concentration risk, particularly given Liquidia’s relatively lean pipeline and limited number of near-term growth opportunities beyond Yutrepia.
Adding to the risk profile is Liquidia’s ongoing patent dispute with United Therapeutics (UTHR - Free Report) concerning Yutrepia’s use in PH-ILD. Management has stated that an adverse ruling could result in royalty obligations or other injunctive or adjunctive relief. With a decision potentially coming at any time, the litigation represents a headwind that could adversely impact Yutrepia’s economics, market opportunity or commercialization prospects.
LQDA’s Valuation and Estimate Movement
Going by the price/sales ratio, LQDA shares currently trade at 6.10X forward sales, higher than the industry’s average of 1.89X but lower than its mean of 14.67X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 earnings per share (EPS) has moved south to $2.57 from $3.02, and that for 2027 EPS has declined to $4.38 from $4.92 in the past 60 days.
Image Source: Zacks Investment Research
Avoid LQDA for Now
Liquidia's products and pipeline candidates for PAH compete across several established and clinically validated treatment pathways. UTHR markets four medicines in the United States to treat PAH, namely Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; under an in-license from Eli Lilly and Company) tablets. Remodulin is approved for both subcutaneous and intravenous use.
Insmed (INSM - Free Report) is also advancing several clinical-stage programs in respiratory diseases, including TPIP and INS1148. TPIP is an inhaled dry powder formulation of the treprostinil prodrug treprostinil palmitil, which may offer a differentiated product profile for PH-ILD, PAH, PPF and IPF.
Despite Yutrepia’s strong launch and encouraging commercial traction, Liquidia’s investment case remains exposed to several meaningful risks. The company continues to be heavily dependent on Yutrepia for growth, while its relatively lean pipeline provides limited diversification.
Any slowdown in prescription growth, reimbursement challenges or increasing competitive pressure could therefore have a material impact on Liquidia’s revenue trajectory and overall growth prospects.
The ongoing patent litigation with UTHR over Yutrepia’s use in PH-ILD represents another significant overhang. An adverse ruling could restrict commercialization, remove the PH-ILD indication or result in monetary damages, creating substantial uncertainty around Yutrepia’s long-term commercial opportunity.
Meanwhile, competition from established PAH therapies could make it increasingly difficult for Yutrepia to sustain its momentum and capture meaningful market share.
While 2026 and 2027 EPS estimates have declined, rising R&D expenses could further weigh on profitability and limit the potential for meaningful earnings leverage in the near term.
Overall, LQDA’s heavy reliance on Yutrepia, ongoing litigation risk, competitive pressures, elevated valuation and rising costs create an unfavorable risk-reward profile.
Hence, we recommend that both current and prospective investors avoid the stock for now.
LQDA has a Zacks Rank #4 (Sell) at present.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.